554720
trans-Retinoic Acid
Potent modulator of growth and differentiation. Inhibits melanocyte adhesion, motility, and growth.
別名:
trans-Retinoic Acid, Tretinoin, ATRA, Vitamin A Acid
ログインで組織・契約価格をご覧ください。
サイズを選択してください
表示を変更する
この商品について
Assay:
≥95% (by assay)
Form:
solid
Storage condition:
OK to freeze, desiccated (hygroscopic), protect from light
description
Merck USA index - 14, 8165
Quality Segment
assay
≥95% (by assay)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, desiccated (hygroscopic), protect from light
color
yellow
solubility
DMSO: 25 mg/mL
shipped in
ambient
storage temp.
2-8°C
SMILES string
OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(CCCC1(C)C)C
InChI
1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14+
InChI key
SHGAZHPCJJPHSC-YCNIQYBTSA-N
General description
Potent modulator of growth and differentiation. Exerts its effects by binding to nuclear retinoic acid receptors (RARs) which directly regulate gene expression. Inhibits melanocyte adhesion, motility, and growth. Has keratolytic activity. Induces differentiation of tumor cells of neural origin. Induces apoptosis in acute promyelocytic carcinoma cells. PROTECT FROM AIR.
Application
- All-trans-retinoic acid modulates glycolysis via H19 and telomerase: the role of mir-let-7a in estrogen receptor-positive breast cancer cells.: This research reveals how all-trans-retinoic acid influences glycolysis in breast cancer cells by modulating H19 and telomerase, demonstrating its potential in breast cancer therapy (El Habre et al., 2024).
- Retinoic acid tiers mitochondrial metabolism to Sertoli Cell-Mediated efferocytosis via a non-RAR-dependent mechanism.: The study explores the role of retinoic acid in linking mitochondrial metabolism to efferocytosis in Sertoli cells, providing insights into its non-RAR-dependent mechanisms and potential applications in reproductive biology (Wu et al., 2024).
- Combined treatment of All-trans retinoic acid with Tamoxifen suppresses ovarian cancer.: This article discusses the synergistic effects of combining all-trans-retinoic acid with tamoxifen in suppressing ovarian cancer, highlighting a promising therapeutic strategy for ovarian cancer patients (Xu et al., 2024).
Packaging
Packaged under inert gas
Preparation Note
Following reconstitution, store in the refrigerator (4°C). DMSO stock solutions are stable for up to 2 weeks at 4°C.
Other Notes
Tosi, P., et al. 1994. Leuk. Lymphoma14, 503.
Clagett-Dame, M., et al. 1993. Arch. Biochem. Biophys.300, 684.
Labbaye, C., et al. 1993. Blood81, 475.
Sakashita, A., et al. 1993. Blood81, 1009.
Situ, R., et al. 1993. Dermatology186, 38.
Tini, M., et al. 1993. Genes Develop.7, 295.
Leid, M., et al. 1992. Trends Biochem. Sci.17, 427.
Sharpe, C.R. 1991. Neuron7, 239.
Thaller, C. and Eichele, G. 1990. Nature345, 815.
Clagett-Dame, M., et al. 1993. Arch. Biochem. Biophys.300, 684.
Labbaye, C., et al. 1993. Blood81, 475.
Sakashita, A., et al. 1993. Blood81, 1009.
Situ, R., et al. 1993. Dermatology186, 38.
Tini, M., et al. 1993. Genes Develop.7, 295.
Leid, M., et al. 1992. Trends Biochem. Sci.17, 427.
Sharpe, C.R. 1991. Neuron7, 239.
Thaller, C. and Eichele, G. 1990. Nature345, 815.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Harmful & Carcinogenic / Teratogenic (E)
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Repr. 1B - Skin Irrit. 2
保管分類
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable